Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1995 Apr 15;152(8):1195–1197.

The breast cancer research scandal: addressing the issues.

C Weijer
PMCID: PMC1337806  PMID: 7736369

Abstract

The three claims put forward by Dr. Roger Poisson to rationalize his enrollment of ineligible subjects in clinical trials do not justify research fraud. None the less, certain lessons for the conduct of clinical research can be learned from the affair: experimental therapies should be made available to technically ineligible subjects when no effective therapy exists for their disease; further research must investigate the possible benefits of clinical-trial participation; broadly based, pragmatic trials must be regarded as the ideal model; and each eligibility criterion in a clinical-trial protocol should be justified.

Full text

PDF
1195

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angell M., Kassirer J. P. Setting the record straight in the breast-cancer trials. N Engl J Med. 1994 May 19;330(20):1448–1450. doi: 10.1056/NEJM199405193302010. [DOI] [PubMed] [Google Scholar]
  2. Begg C. B., Engstrom P. F. Eligibility and extrapolation in cancer clinical trials. J Clin Oncol. 1987 Jun;5(6):962–968. doi: 10.1200/JCO.1987.5.6.962. [DOI] [PubMed] [Google Scholar]
  3. Boros L., Chuang C., Butler F. O., Bennett J. M. Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation. Cancer. 1985 Nov 1;56(9):2161–2169. doi: 10.1002/1097-0142(19851101)56:9<2161::aid-cncr2820560904>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  4. Buyse M. E. The case of loose inclusion criteria in clinical trials. Acta Chir Belg. 1990 May-Jun;90(3):129–131. [PubMed] [Google Scholar]
  5. Freedman Benjamin. Multicenter trials and subject eligibility: should local IRBs play a role? IRB. 1994 Jan-Apr;16(1-2):1–6. [PubMed] [Google Scholar]
  6. Hjorth M., Holmberg E., Rödjer S., Westin J. Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. The Myeloma Group of Western Sweden. Br J Haematol. 1992 Jan;80(1):55–61. doi: 10.1111/j.1365-2141.1992.tb06400.x. [DOI] [PubMed] [Google Scholar]
  7. Karjalainen S., Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ. 1989 Oct 28;299(6707):1069–1072. doi: 10.1136/bmj.299.6707.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lennox E. L., Stiller C. A., Jones P. H., Wilson L. M. Nephroblastoma: treatment during 1970-3 and the effect on survival of inclusion in the first MRC trial. Br Med J. 1979 Sep 8;2(6190):567–569. doi: 10.1136/bmj.2.6190.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lowry F. Dr. Roger Poisson: "I have learned my lesson the hard way". CMAJ. 1994 Sep 15;151(6):835–837. [PMC free article] [PubMed] [Google Scholar]
  10. Meadows A. T., Kramer S., Hopson R., Lustbader E., Jarrett P., Evans A. E. Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment. Cancer Invest. 1983;1(1):49–55. doi: 10.3109/07357908309040932. [DOI] [PubMed] [Google Scholar]
  11. Mosteller F. Innovation and evaluation. Science. 1981 Feb 27;211(4485):881–886. doi: 10.1126/science.6781066. [DOI] [PubMed] [Google Scholar]
  12. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rich S. Prostacyclin and primary pulmonary hypertension. Ann Intern Med. 1994 Sep 15;121(6):463–464. doi: 10.7326/0003-4819-121-6-199409150-00012. [DOI] [PubMed] [Google Scholar]
  14. Salisbury D. A., Schechter M. T. AIDS trials, civil liberties and the social control of therapy: should we embrace new drugs with open arms? CMAJ. 1990 May 15;142(10):1057–1062. [PMC free article] [PubMed] [Google Scholar]
  15. Stiller C. A., Draper G. J. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. Arch Dis Child. 1989 May;64(5):657–661. doi: 10.1136/adc.64.5.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stiller C. A. Survival of patients with cancer. BMJ. 1989 Oct 28;299(6707):1058–1059. doi: 10.1136/bmj.299.6707.1058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Vanderpool H. Y., Weiss G. B. False data & the therapeutic misconception: two urgent problems in research ethics. False data and last hopes: enrolling ineligible patients in clinical trials. Hastings Cent Rep. 1987 Apr;17(2):16–19. [PubMed] [Google Scholar]
  18. Yusuf S., Held P., Teo K. K., Toretsky E. R. Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med. 1990 Jan-Feb;9(1-2):73–86. doi: 10.1002/sim.4780090114. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES